Lv01
0 积分 2024-01-29 加入
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
1小时前
已完结
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial
1小时前
已完结
Cemiplimab monotherapy as first‐line treatment of patients with brain metastases from advanced non–small cell lung cancer with programmed cell death‐ligand 1 ≥50%
1小时前
待确认
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
1小时前
已完结
Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases
1小时前
已完结
[Expert consensus on diagnosis and treatment of malignant pleural effusion caused by lung cancer]
15天前
已完结
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
1个月前
已完结
Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature
1个月前
已完结
Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies
1个月前
已完结
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR
1个月前
已完结
皖公网安备34019202002308
